Clinical Takeaway
In this pilot trial of 20 adults with diagnosed insomnia, a single oral dose of 10 mg THC combined with 200 mg CBD reduced total sleep time compared to placebo, suggesting that at least at these doses, cannabinoids did not improve objective sleep duration. These findings highlight that patient-reported sleep benefits from cannabinoids may not align with measurable changes in sleep architecture, and next-day alertness effects warrant further investigation. Clinicians should counsel patients that current evidence does not reliably support cannabinoids as first-line sleep aids for insomnia disorder.
#9 Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.
Citation: Suraev Anastasia et al.. Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.. Journal of sleep research. 2026. PMID: 40631525.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0
This pilot study provides the first high-resolution neurophysiological characterization of how a THC/CBD combination affects sleep architecture in patients with diagnosed insomnia disorder, moving beyond subjective patient reports to objective EEG-derived measures of sleep quality and continuity. Understanding whether cannabinoids improve sleep without impairing next-day cognitive function is essential for clinical decision-making, as current evidence remains limited despite widespread patient use. The high-density EEG methodology enables detection of subtle sleep stage alterations and cortical activity changes that standard polysomnography cannot capture, potentially revealing mechanisms underlying cannabinoid efficacy or harm in this population.
Methodological Considerations:
- Self-reported outcomes — recall and social-desirability bias risk
Abstract: Cannabinoids, particularly Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), have gained popularity as alternative sleep aids; however, their effects on sleep architecture and next-day function remain poorly understood. Here, in a pilot trial, we examined the effects of a single oral dose containing 10 mg THC and 200 mg CBD (THC/CBD) on objective sleep outcomes and next-day alertness using 256-channel high-density EEG in 20 patients with DSM-5 diagnosed insomnia disorder (16 female; mean (SD) age, 46.1 (8.6) years). We showed that THC/CBD decreased total sleep time (-24.5 min, p = 0.05, d = -0.5) with no change in wake after sleep onset (+10.7 min, p > 0.05) compared to placebo. THC/CBD also significantly decreased time spent in REM sleep (-33.9 min, p < 0.001, d = -1.5) and increased latency to REM sleep (+65.6 min, p = 0.008, d = 0.7). High-density EEG analysis revealed regional decreases in gamma activity during N2 sleep, and in delta activity during N3 sleep, and a regional increase in beta and alpha activity during REM sleep. While there was no observed change in next-day objective alertness, a small but significant increase in self-reported sleepiness was noted with THC/CBD (+0.42 points, p = 0.02, d = 0.22). No changes in subjective sleep quality, cognitive performance, or simulated driving performance were observed. These findings suggest that a single dose of cannabinoids, particularly THC, may acutely influence sleep, primarily by suppressing REM sleep, without noticeable next-day impairment (≥ 9 h post-treatment). Australian New Zealand Clinical Trial Registry (ACTRN12619000714189) https://www.anzctr.org.au/.
😴 This pilot study provides useful high-resolution neurophysiological data on a single THC/CBD dose in insomnia patients, but several limitations warrant cautious interpretation for clinical practice. The small sample size of 20 participants, predominance of female subjects (80%), and single-dose design limit generalizability to diverse patient populations and long-term use patterns that patients typically pursue. While high-density EEG offers mechanistic insights into sleep architecture changes, the study does not clarify whether observed neurophysiological effects translate to clinically meaningful improvements in daytime function, symptom burden, or quality of life—the outcomes patients actually care about. Important confounders remain uncontrolled, including baseline cannabinoid exposure, concurrent medications, and genetic variations in cannabinoid metabolism that significantly affect individual response. For now, this work suggests that the THC/CBD ratio tested warrants further investigation in larger, longer-duration trials, but clinicians should discuss both the promise and the genuine evidence gaps with patients seeking cannabis for insom
| |